Novartis Says Sandoz Biosimilar Met Primary Endpoints in Trial
19 Setembro 2022 - 3:06AM
Dow Jones News
By Joshua Kirby
Novartis AG said Monday that an integrated trial of denosumab, a
proposed biosimilar developed by its subsidiary Sandoz, generated
positive results.
Denosumab is indicated for the treatment of various conditions
including osteoporosis.
An integrated Phase 1-3 study of the biosimilar met its primary
endpoints of matching reference medicines and contributing to
demonstration of similarity, the Swiss drugmaker said.
Write to Joshua Kirby at joshua.kirby@wsj.com;
@joshualeokirby
(END) Dow Jones Newswires
September 19, 2022 01:51 ET (05:51 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
